The Latest Breaking News from Edwards Lifesciences

Despite Edwards Lifesciences’ underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Edwards Lifesciences is expected to release its second-quarter earnings this month, and analysts expect a single-digit profit increase.

Edwards Lifesciences has recently underperformed the Healthcare sector, but Wall Street analysts anticipate a modest upside for the stock.

Pharmaceutical equipment firms are funding NHS staff and training while promoting sales

Upgrades

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Someone with a lot of money to spend has taken a bullish stance on Edwards Lifesciences (NYSE:EW). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 166.36% since its last report. The company recently reported that it has 5.87 million shares sold short, which is 2.85% of all regular shares that are available for trading.

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 6.33% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 0.84% of all regular shares that are available for trading.

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 16.51% on an annualized basis producing an average annual return of 22.72%. Currently, Edwards Lifesciences has a market capitalization of $55.48 billion.

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…